# Rituximab in New Onset Type 1 Diabetes

> **NCT00279305** · PHASE2 · COMPLETED · sponsor: **National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)** · enrollment: 87 (actual)

## Conditions studied

- Type 1 Diabetes Mellitus

## Interventions

- **DRUG:** Anti-CD20 (rituximab)
- **DRUG:** Placebo Comparator

## Key facts

- **NCT ID:** NCT00279305
- **Lead sponsor:** National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-08
- **Primary completion:** 2009-04
- **Final completion:** 2009-11
- **Target enrollment:** 87 (ACTUAL)
- **Last updated:** 2020-05-06

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00279305

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00279305, "Rituximab in New Onset Type 1 Diabetes". Retrieved via AI Analytics 2026-09-14 from https://api.ai-analytics.org/clinical/NCT00279305. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*